Anti-PD-1/anti 4-1BB combination treatment increases the expression of PD-L1 on tumor cells by producing IFN-γ, thus providing a rational for simultaneous treatment of tumor with these two proteins [4, 28]. The gene discussed is CD274; the disease is neoplasm.